Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Risk of Secondary Hematologic Malignancy Not Significantly Increased by PARP Inhibitors

2020 Year in Review - Ovarian Cancer - Ovarian Cancer

Although researchers noted a trend toward increased incidence of secondary hematologic malignancy in patients with newly diagnosed ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors, the difference was not statistically significant.

In women with advanced ovarian cancer who are treated with PARP inhibitor maintenance or as first-line treatment, the risk of secondary hematologic malignancies is not increased significantly. In a combined meta-analysis of 7 phase 3 randomized controlled trials of women with advanced ovarian cancer, the overall incidence of secondary hematologic malignancies was 0.80% in the women randomized to PARP inhibitors as maintenance compared with 0.47% in controls (risk ratio [RR], 1.45; 95% confidence interval [CI], 0.68-3.07; P = .34). Data were reported by Thura W. Htut, MBBS, MRCP, Haematology Fellow, Aberdeen Royal Infirmary, Scotland, UK, and colleagues in poster format at this year’s virtual scientific program of the American Society of Clinical Oncology.

A total of 4445 patients were included from the ARIEL3, ENGOT-OV16/NOVA, and SOLO-2 clinical trials in which PARP inhibitors were studied in the treatment of recurrent ovarian cancer, and the VELIA, PRIMA, SOLO-1, and PAOLA-1 clinical trials in which PARP inhibitors were studied as first-line treatment. In the study arm, treatment regimens were olaparib, niraparib, rucaparib, veliparib, or olaparib plus bevacizumab. The control arm consisted of placebo or bevacizumab. Randomization was 2:1 in all studies.

The incidence of a secondary hematologic malignancy in patients with newly diagnosed ovarian cancer (N = 3044) was 0.59% in the group randomized to PARP inhibitors compared with 0.09% in the control group. The difference was not statistically significant (RR, 2.7; 95% CI, 0.7-10.37; P = .15) despite a numeric trend toward increased incidence in patients receiving PARP inhibitors.

The secondary hematologic malignancy rate in women with recurrent ovarian cancer (N = 1401) was identical (1.28%) in the PARP inhibitor and control arms (RR, 0.96; 95% CI, 0.38-2.46; P = .94).

Within the PARP inhibitor group, estimates were derived for patients treated with olaparib or niraparib. The rate of secondary hematologic malignancy for those treated with olaparib was 1.3% compared with 1% in the controls (RR, 1.24; 95% CI, 0.46-3.31; P = .67). The rates were identical among patients assigned to niraparib; 0.47% developed a secondary hematologic malignancy in both the niraparib and control groups (RR, 1.28; 95% CI, 0.30-5.45; P = .74).

Source: Htut T, et al. J Clin Oncol. 2020;38(15_suppl). Abstract 12076.

Related Items
Maintenance with PARP Inhibitors Extends Survival in Patients with Advanced Ovarian Cancer
William King
TON - June 2021 Vol 14, No 3 published on June 22, 2021 in Ovarian Cancer
Ovarian Cancer Year In Review Introduction
2020 Year in Review - Ovarian Cancer published on January 20, 2021 in Ovarian Cancer
First-Line Maintenance Setting in Patients with Recurrent Ovarian Cancer: Individualized Starting Dose of Niraparib Recommended
2020 Year in Review - Ovarian Cancer published on January 20, 2021 in Ovarian Cancer
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
A Systematic Review of Robotic Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
Phase 2 OVARIO Study: Promising Survival Rates with Niraparib plus Bevacizumab in Women with Advanced Ovarian Cancer
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
Starting Dose of Rucaparib in Patients with Recurrent Ovarian Cancer Based on a Pooled Analysis
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
The Efficacy of Niraparib in Patients with Advanced Ovarian Cancer Extends to All Biomarker Subgroups
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
Phase 3 SOLO1 Subgroup Analysis Based on Olaparib-Treated, Low- and High-Risk Patients with Ovarian Cancer and BRCA Mutation
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
NOVA Clinical Trial versus Real-World Data: Niraparib Treatment Outcomes in Patients with BRCA–Wild-Type, Platinum-Sensitive, Recurrent Ovarian Cancer
2020 Year in Review - Ovarian Cancer published on January 19, 2021 in Ovarian Cancer
Last modified: July 22, 2021